These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. Rosenbaum E; Carducci MA Expert Opin Pharmacother; 2003 Jun; 4(6):875-87. PubMed ID: 12783585 [TBL] [Abstract][Full Text] [Related]
3. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Papatsoris AG; Karamouzis MV; Papavassiliou AG Curr Med Chem; 2005; 12(3):277-96. PubMed ID: 15723619 [TBL] [Abstract][Full Text] [Related]
4. Treatment options in hormone-refractory prostate cancer: current and future approaches. Harris KA; Reese DM Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129 [TBL] [Abstract][Full Text] [Related]
10. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Mancuso A; Oudard S; Sternberg CN Crit Rev Oncol Hematol; 2007 Feb; 61(2):176-85. PubMed ID: 17074501 [TBL] [Abstract][Full Text] [Related]
11. Clinical trials in metastatic prostate cancer--has there been real progress in the past decade? Bhandari MS; Petrylak DP; Hussain M Eur J Cancer; 2005 Apr; 41(6):941-53. PubMed ID: 15808960 [TBL] [Abstract][Full Text] [Related]
12. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Antonarakis ES; Carducci MA; Eisenberger MA Cancer Lett; 2010 May; 291(1):1-13. PubMed ID: 19717225 [TBL] [Abstract][Full Text] [Related]
13. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED; J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632 [TBL] [Abstract][Full Text] [Related]
14. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Berry W; Eisenberger M Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869 [TBL] [Abstract][Full Text] [Related]
16. Progress of molecular targeted therapies for prostate cancers. Fu W; Madan E; Yee M; Zhang H Biochim Biophys Acta; 2012 Apr; 1825(2):140-52. PubMed ID: 22146293 [TBL] [Abstract][Full Text] [Related]
17. Drug development in prostate cancer. Ripple GH; Wilding G Semin Oncol; 1999 Apr; 26(2):217-26. PubMed ID: 10597732 [TBL] [Abstract][Full Text] [Related]
18. [New perspectives in the drug therapy of hormone-resistant prostate cancer]. Vorob'ev NA; Nosov AK; Vorob'ev AV; Moiseenko VM Vopr Onkol; 2010; 56(6):645-53. PubMed ID: 21395118 [No Abstract] [Full Text] [Related]
19. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Lorenzo GD; Bianco R; Tortora G; Ciardiello F Clin Prostate Cancer; 2003 Jun; 2(1):50-7. PubMed ID: 15046685 [TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. Merino M; Pinto A; González R; Espinosa E Eur J Cancer; 2011 Aug; 47(12):1846-51. PubMed ID: 21600762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]